Clinical trial
Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of…
NCT00281658 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00281658 |
|---|---|
| Title | Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2 |
| Official title | A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study of Lapatinib (GW572016) in Combination With Paclitaxel Versus Paclitaxel Plus Placebo in Subjects With ErbB2 Amplified Metastatic Breast Cancer |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Drug |
| Interventions | Lapatinib (GW572016) oral tablets, Paclitaxel infusion, Placebo |
| Enrollment | 444 |
| Start date | Jan 2, 2006 |
| Primary completion | Jun 18, 2010 |
| Completion | Nov 23, 2021 |
| First posted | Jan 25, 2006 |
| Last update posted | Feb 10, 2023 |
| Countries | Brazil, China, Hong Kong, Pakistan, Peru, Russia, Thailand, Ukraine |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: